Showing results (241-250 of 288) with videos related to
Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2022
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive ScoreBarbara Burtness, Danny Rischin, Richard Greil, et al.Acta Oncologica (Stockholm, Sweden)|February 10, 2022
International assessment of interobserver reproducibility of flap delineation in head and neck carcinomaArnaud Beddok, Leslie Guzene, Alexandre Coutte, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2022
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 StudyKevin J Harrington, Barbara Burtness, Richard Greil, et al.Implementation Science : IS|March 5, 2021
Care to Quit: a stepped wedge cluster randomised controlled trial to implement best practice smoking cessation care in cancer centresChristine L Paul, Graham Warren, Shalini Vinod, et al.Future Oncology (London, England)|June 4, 2020
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, et al.Health Services & Outcomes Research Methodology|October 4, 2022
Building staff capability, opportunity, and motivation to provide smoking cessation to people with cancer in Australian cancer treatment centres: development of an implementation intervention framework for the Care to Quit cluster randomised controlled trialAnnika Ryan, Alison Luk Young, Jordan Tait, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2011
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancerMichael S Anglesio, Joshy George, Hagen Kulbe, et al.Gynecologic Oncology|September 12, 2020
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancerDanny Rischin, Marta Gil-Martin, Antonio González-Martin, et al.Oral Oncology|December 15, 2023
Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-PacificYe Guo, Torahiko Nakashima, Byoung Chul Cho, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2018
Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 TrialSandro Virgilio Porceddu, Mathias Bressel, Michael Geoffrey Poulsen, et al.Pageof 29